Developer docs
API playgroundTry for free, no card

Search company profiles

Carcinotech

Full company profile

uuid0002p2k

Namestring
Carcinotech
Legal namestring
Carcinotech Ltd.
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEdinburgh, United Kingdom
HQ citystring
Edinburgh
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D bioprinting services, preclinical oncology models, patient-derived tumor models, cancer drug screening, tumor biopsy sourcing
Industry1 code
PRIMARYHLAGAFAG
Carcinogenicity Studies
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Preclinical Oncology Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Preclinical Oncology Services
TypeProfessional Services
Description

Provides end-to-end preclinical oncology services including biopsy sourcing, 3D tumor printing, and assay development. Services are delivered directly to biotech and pharmaceutical clients for cancer research and drug development applications.

carcinotech.co.uk
2Custom Assay Development
TypeProfessional Services
Description

Bridges resource gaps for clients by designing and executing custom assays on their behalf, delivering scientific insights for drug testing and optimization.

carcinotech.com
3Patient-Derived Tumor Models
TypeOne Time License
Description

Provides assay-ready, patient-derived 3D-printed tumor models for drug testing, optimization, and precision medicine applications.

carcinotech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Carcinotech manufactures 3D-bioprinted, patient-derived living tumor models from biopsies for use in preclinical oncology research. The company offers end-to-end services covering biopsy sourcing, 3D tumor development that retains native microenvironments, and custom oncology assay execution for biotech and pharmaceutical clients. These models are used for early drug discovery, preclinical testing, and personalized medicine applications across multiple cancer therapy modalities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 50+ diverse tumor biopsies available for research studies
+2 more records
Product overview1 text field

Carcinotech offers a unified preclinical oncology services platform centered on its Carcino3D™ 3D bioprinting technology. The platform comprises biopsy sourcing services, 3D tumor development, and oncology assay services. These services support early drug discovery, preclinical testing, and personalized medicine applications across multiple cancer therapy modalities including immunotherapies, monoclonal antibodies, hormone therapies, cancer vaccines, targeted therapies, oncolytic virus therapies, radioimmunotherapies, chemotherapies, and gene therapies. The company also provides specific tumor model products including lung, ovarian, and GBM models.

Product and service2 records
1Carcino3D™ Platform
Category3D Bioprinting Technology Platform
Description

Carcinotech's core proprietary 3D bioprinting technology platform that creates patient-derived micro-tumors from biopsies for drug screening and personalized cancer treatment testing. Enables precise simulation of tumor microenvironments for biotech and pharmaceutical clients.

2Biopsy Sourcing Service
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Company collaborates with global partners to improve predictive models for cancer therapies and advance oncology drug development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Cypre is an early-stage company developing 3D tumor models and screening platforms for cancer drug discovery. It competes in the same niche of 3D-printed or 3D-cultured tumor models for preclinical oncology.

TypeEmerging player
Description

Regemat3D develops 3D bioprinting technology for tissue and disease modeling applications including oncology research. It shares technology overlap with Carcinotech in the 3D bioprinting space.

TypeDirect peer
Description

Crown Bioscience is a leading preclinical CRO specializing in oncology with extensive patient-derived xenograft (PDX) and organoid services. It directly competes with Carcinotech in providing preclinical oncology models for drug development to pharma and biotech clients.

TypeDirect peer
Description

InSphero specializes in 3D cell culture technology and organoid models for drug discovery and toxicology applications. It competes with Carcinotech in offering physiologically relevant 3D in vitro models for pharmaceutical preclinical research.

TypeDirect peer
Description

MIMETAS develops organ-on-chip and 3D tissue models for preclinical drug testing across multiple therapeutic areas including oncology. It overlaps with Carcinotech in providing 3D biology solutions for pharma drug development.

6CN Bio
TypeDirect peer
Description

CN Bio provides organ-on-chip and microphysiological systems for drug discovery, including oncology applications. It represents a comparable emerging player in the 3D biology preclinical services market.

TypeBroad incumbent
Description

Charles River Laboratories is a large incumbent CRO offering comprehensive preclinical oncology services alongside broader drug development capabilities. It represents the scaled incumbent competing for the same pharma preclinical budgets as Carcinotech.

TypeBroad incumbent
Description

Molecular Devices provides 3D biology instrumentation, imaging, and assay solutions for drug discovery. It operates as an enabling platform provider to the 3D biology market in which Carcinotech operates.

TypeEmerging player
Description

Lena Biosciences focuses on 3D bioprinting and tissue engineering for drug screening applications. It shares 3D bioprinting technology overlap with Carcinotech's Carcino3D™ platform.

TypeEmerging player
Description

SynVivo provides microfluidic organ-on-chip platforms for preclinical drug testing and disease modeling. It overlaps with Carcinotech in offering human-relevant preclinical models for drug development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Carcinotech

Preclinical Oncology Servicescarcinotech.co.uk

Carcinotech firmographics

Firmographics
Name
Carcinotech
Legal name
Carcinotech Ltd.
Website
https://carcinotech.co.uk
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Carcinotech industry classification

Industry
Product category
Preclinical Oncology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAFAG
Carcinogenicity Studies
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • 3D bioprinting services
  • Preclinical oncology models
  • Patient-derived tumor models
  • Cancer drug screening
  • Tumor biopsy sourcing

Where Carcinotech is headquartered

Location

Headquarters

HQ city
Edinburgh
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Carcinotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Preclinical Oncology Services: Provides end-to-end preclinical oncology services including biopsy sourcing, 3D tumor printing, and assay development. Services are delivered directly to biotech and pharmaceutical clients for cancer research and drug development applications.
  2. Custom Assay Development: Bridges resource gaps for clients by designing and executing custom assays on their behalf, delivering scientific insights for drug testing and optimization.
  3. Patient-Derived Tumor Models: Provides assay-ready, patient-derived 3D-printed tumor models for drug testing, optimization, and precision medicine applications.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Carcinotech product offering

Product offering

Core offering

Carcinotech manufactures 3D-bioprinted, patient-derived living tumor models from biopsies for use in preclinical oncology research. The company offers end-to-end services covering biopsy sourcing, 3D tumor development that retains native microenvironments, and custom oncology assay execution for biotech and pharmaceutical clients. These models are used for early drug discovery, preclinical testing, and personalized medicine applications across multiple cancer therapy modalities.

Product overview

Carcinotech offers a unified preclinical oncology services platform centered on its Carcino3D™ 3D bioprinting technology. The platform comprises biopsy sourcing services, 3D tumor development, and oncology assay services. These services support early drug discovery, preclinical testing, and personalized medicine applications across multiple cancer therapy modalities including immunotherapies, monoclonal antibodies, hormone therapies, cancer vaccines, targeted therapies, oncolytic virus therapies, radioimmunotherapies, chemotherapies, and gene therapies. The company also provides specific tumor model products including lung, ovarian, and GBM models.

Differentiator

Problem solved

Functional benefit

Products and services

  • Carcino3D™ Platform Carcinotech's core proprietary 3D bioprinting technology platform that creates patient-derived micro-tumors from biopsies for drug screening and personalized cancer treatment testing. Enables precise simulation of tumor microenvironments for biotech and pharmaceutical clients.
  • Biopsy Sourcing Service

Quantifiable outcome

  • 50+ diverse tumor biopsies available for research studies
  • +2 more outcomes

Companies that use Carcinotech

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Carcinotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Carcinotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Global Partners (unspecified)coreStrategic or Co-development PartnerCompany collaborates with global partners to improve predictive models for cancer therapies and advance oncology drug development.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Carcinotech competitors and assessment

Company assessment

Emerging players

  • Cypre: Cypre is an early-stage company developing 3D tumor models and screening platforms for cancer drug discovery. It competes in the same niche of 3D-printed or 3D-cultured tumor models for preclinical oncology.
  • Regemat3D: Regemat3D develops 3D bioprinting technology for tissue and disease modeling applications including oncology research. It shares technology overlap with Carcinotech in the 3D bioprinting space.
  • Lena Biosciences: Lena Biosciences focuses on 3D bioprinting and tissue engineering for drug screening applications. It shares 3D bioprinting technology overlap with Carcinotech's Carcino3D™ platform.
  • SynVivo: SynVivo provides microfluidic organ-on-chip platforms for preclinical drug testing and disease modeling. It overlaps with Carcinotech in offering human-relevant preclinical models for drug development.

Direct peers

  • Crown Bioscience: Crown Bioscience is a leading preclinical CRO specializing in oncology with extensive patient-derived xenograft (PDX) and organoid services. It directly competes with Carcinotech in providing preclinical oncology models for drug development to pharma and biotech clients.
  • InSphero: InSphero specializes in 3D cell culture technology and organoid models for drug discovery and toxicology applications. It competes with Carcinotech in offering physiologically relevant 3D in vitro models for pharmaceutical preclinical research.
  • MIMETAS: MIMETAS develops organ-on-chip and 3D tissue models for preclinical drug testing across multiple therapeutic areas including oncology. It overlaps with Carcinotech in providing 3D biology solutions for pharma drug development.
  • CN Bio: CN Bio provides organ-on-chip and microphysiological systems for drug discovery, including oncology applications. It represents a comparable emerging player in the 3D biology preclinical services market.

Broad incumbents

  • Charles River Laboratories: Charles River Laboratories is a large incumbent CRO offering comprehensive preclinical oncology services alongside broader drug development capabilities. It represents the scaled incumbent competing for the same pharma preclinical budgets as Carcinotech.
  • Molecular Devices: Molecular Devices provides 3D biology instrumentation, imaging, and assay solutions for drug discovery. It operates as an enabling platform provider to the 3D biology market in which Carcinotech operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Carcinotech social profiles

Digital presence

Carcinotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Carcinotech leadership team

Management profile

Number of profiles

Profiles1 record

Carcinotech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Carcinotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carcinotech

What does Carcinotech do?

Carcinotech manufactures 3D-bioprinted, patient-derived living tumor models from biopsies for use in preclinical oncology research. The company offers end-to-end services covering biopsy sourcing, 3D tumor development that retains native microenvironments, and custom oncology assay execution for biotech and pharmaceutical clients. These models are used for early drug discovery, preclinical testing, and personalized medicine applications across multiple cancer therapy modalities.

Is Carcinotech a public or private company?

Carcinotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Carcinotech founded?

Carcinotech was founded in 2018. It employs 11 to 50 people.

Where is Carcinotech based?

Carcinotech is headquartered in Edinburgh, United Kingdom, in the Europe region.

How does Carcinotech make money?

Three revenue lines are on record. Preclinical Oncology Services are the primary driver. The others are custom Assay Development and patient-Derived Tumor Models.

Who are Carcinotech's main competitors?

Emerging players on record are Cypre, Regemat3D, Lena Biosciences and SynVivo. Direct peers are Crown Bioscience, InSphero, MIMETAS and CN Bio. Broad incumbents are Charles River Laboratories and Molecular Devices.

Does Carcinotech have an API?

No public API is recorded for Carcinotech.

What industry is Carcinotech in?

Carcinotech's product category is Preclinical Oncology Services. Its primary akta.pro industry code is HLAGAFAG, Carcinogenicity Studies. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessCloudCarcinotech raises £4.2m to develop 3D-printed micro-tumour techCarcinotech raised £4.2 million to expand its 3D-printed micro-tumour technology, with US expansion planned later this year. The Edinburgh spinout's Carcinino3D uses patient-derived cells to simulate tumour microenvironments, accelerating ethical drug screening. The company also announced a partnership with CELLINK in October.Pulse 2.0Carcinotech: 3D Printed Micro-Tumor Technology Company Raises $5.3 MillionCarcinotech, a company specializing in 3D printed micro-tumor technology, has raised $5.3 million in funding to support its expansion into the US market. The investment was led by Eos Advisory and includes participation from the Investment Fund for Scotland, Scottish Enterprise, and several other investors. This capital will be used to replicate existing European industry partnerships in North America.Tech Funding NewsMedical marvel: This female-founded startup uses 3D bioprinting to mimic tumour environment for cancer treatment, gets £4.2M funding — TFNCarcinotech, a biotech startup based in Edinburgh, raised £4.2 million in its latest funding round, with Eos Advisory leading the investment. The company plans to use the funds to expand its operations in the UK, Europe, and the US while focusing on developing 3D bioprinted tumor models for cancer treatment. This funding marks a significant milestone as it is the first equity deal from the newly launched Investment Fund for Scotland.LinkedInWe are proud to announce that we have raised £4.2 million of funding to support our Carcino3D™ technology and facilitate US expansion in 2024. This investment marks a pivotal milestone for the…Carcinotech has successfully raised £4.2 million to support its Carcino3D™ technology and plans to expand into the US market in 2024. This funding marks a significant milestone, fostering partnerships and enhancing cancer drug testing capabilities. The investment was led by Eos Advisory and includes support from multiple investors and the Investment Fund for Scotland managed by Maven Capital Partners.EdMed tech startup Carcinotech raises £4.2mMed tech startup Carcinotech has raised £4.2 million in funding to support its expansion into the US market following traction in the UK and Europe. The capital, led by Eos Advisory with participation from Old College Capital and other investors, will be used to scale its Carcino3D technology for 3D printed micro-tumours that accelerate ethical drug screening. This financial backing follows a recent partnership with CELLINK to develop advanced cell line cancer models.UKTNEdinburgh startup making 3D-printed tumours raises £4.2mEdinburgh-based health startup Carcinotech has raised £4.2 million in funding to further develop its 3D-printed micro-tumour technology for cancer drug testing. The investment round, led by Eos Advisory and the Investment Fund for Scotland, will support the company's planned expansion into the US market later this year.FinSMEsCarcinotech Raises £4.2M in FundingEdinburgh-based Carcinotech raised £4.2 million in a funding round led by Eos Advisory and supported by several other investors including Scottish Enterprise and Maven Capital Partners. The company intends to use the capital to expand its operations and research and development efforts for its 3D printed micro-tumour technology. This funding supports Carcinotech's goal of accelerating ethical drug screening and personalized cancer treatments.News-Medical3D Printing the Way to New Cancer TreatmentsCarcinotech CEO Ishani Malhotra describes the company's 3D-printed tumor replicas made from patient-derived cells for personalized cancer drug testing. The technology aims to replace animal testing and accelerate treatment development, with plans to enter the US market in 2023.DIGITScottish Investors Provide £1.6m for Life Sciences Company CarcinotechRoslin-based life sciences firm Carcinotech has secured £1.6 million in funding led by TRICAPITAL, with co-investors including Eos Advisory, SIS Ventures, Gabriel, Alba Equity and Scottish Enterprise. The company manufactures 3D-printed tumour models from cancer stem cells for drug discovery trials. CEO Ishani Malhotra said the company will expand commercial partnerships in Europe and North America over the next twelve months.